Drug resistance is increasingly developing amongst nosocomial pathogens (
13,
14). Approximately 0.3% of
P. aeruginosa genes encode agents for antibiotic resistance (
15). The ESBL-positive
P. aeruginosa strains are resistant to the extended-spectrum cephalosporins with several estimated mechanisms (
16). In this study, more than 45% of the ESBL positive wound isolates contained the
blaVEB-1 gene, suggesting that several other mechanisms can also interfere in decreased resistance to third generation cepgalosporins; such as reducing the levels of antibiotics accumulated in bacteria or increasing the expression of efflux pumps that are important in gram negative strains. In the present study, the majority of the wound
P. aeruginosa isolates were resistant to disks of cefpodoxime and augmentin/co-amoxi clav. We observed that most of our wound isolates were sensitive to imipenem and meropenem. Moreover, about 40% of the isolates were resistant to cefpodoxime, aztreonam, ceftriaxone and cefotaxime. The combined disk is routinely used for detection of phenotypic positive ESBLs with use a third generation cephalosporin with or without inhibitory clavulanate (
17). However, resistance to the inhibitor indicates the possible presence of AmpC or other consistent enzymes (
18). Several previous studies that aimed to detect ESBLs have demonstrated a high level of resistance among
P. aeruginosa isolates to antibiotics (
19). In this study, more than half of the wound ESBL positive isolates could amplify
blaVEB-1 (47%). As mentioned above, the antibiotic resistance pattern was considerably at a higher level in ESBL positive isolates (not significant). Interestingly, the
blaVEB-1 was detected in isolates that were resistant to all the used third generation cephalosporins. There are limited results regarding the prevalence of the
blaVEB-1 gene in Middle Eastern countries. Amongst the results from our country, 24% of ESBL positive isolates in the study of Shacheraghi et al. contained this gene (
20). Furthermore, in Tehran, Mirsalehian demonstrated that 49.25% and 31.34% of ESBL positive isolates collected from burn patients amplified
blaPER-1 and
blaVEB-1 genes, respectively (
21). However, in Korea, none of the
P. aeruginosa isolates could amplify the
blaVEB-1 gene (
10). Although we detected this gene at a low prevalence, because of its plasmid borne nature, there is a possibility of rapid transmission amongst gram-negative bacteria. Fortunately, carbapenem resistance was not high, as found by the study of Mirsalehian (
21). However, another study exhibited that 95% of ESBL positive isolates of
P. aeruginosa were resistant to imipenem and meropenem; such findings may be warning of a crisis, as these drugs are the best choices for ESBL positive isolates. In an Iranian study, conducted in the Semnan province during 2010, 88% of gram negative isolates harbored ESBLs (
22). However, Aminzadeh in a study conducted in Tehran during 2011, determined that 13.7% of enteric pathogens (a total of 292 species) were ESBL positive (
23). Khosravi in 2012 investigated several isolates of
Klebsiella pneumonia and found that 47.27% were ESBL positive containing TEM-1 (34.61%), SHV-1 (46.15%) and CTX-M-1 (26.92%) genes (
24). In the research of Fazeli, 71% of
K. pneumonia isolates were ESBL positive (
25). In the study of Kapur from India, 61% of urinary tract pathogens were ESBL positive (
26). For resistant isolates combination therapy (usually including a class of β-lactam and an aminoglycoside) is recommended that would contribute to the curing of pseudomonal infections (
27). Less than half of our wound isolates of
P. aeruginosa produced ESBLs among which an approximate half could amplify the
blaVEB-1 gene. These isolates showed a higher drug resistance compared to ESBL negative strains. On the other hand, the resistance to carbapenems was low.